| abstract |
Disclosed is the use of a pharmaceutical composition adapted for oral administration, comprising ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran) optionally in the form of tautomers, racemates, enantiomers, diastereomers, pharmacologically acceptable acid addition salts, solvates or hydrates thereof, and one or more platelet inhibitors selected from the group consisting of acetylsalicylic acid, clopidogrel and ticlopidine, optionally in the form of the racemates, the enantiomers, the diastereomers and optionally the pharmacologically acceptable acid addition salts and the hydrates thereof and optionally together with one or more pharmaceutically acceptable excipients or carriers. |